In this episode of the Interventional Glaucoma Podcast, Prof. Gus Gazzard speaks with Dr. Marc Töteberg-Harms and Dr. Timothy Hamann about the health economics of interventional glaucoma. They discuss how MIGS can deliver long-term savings and quality-of-life benefits despite higher upfront costs, highlight evidence supporting its cost-effectiveness, and emphasize the growing ethical responsibility for clinicians to discuss MIGS options with eligible cataract patients.
 
The ELIOS system (Bausch & Lomb) is manufactured by MLase GmbH, located at 82110 Germering, Industriestr. 17, Germany and by WEINERT Fiber Optics GmbH, Mittlere-Motsch-Strasse 26, 96515 Sonneberg, Germany. 
ELIOS is CE marked for use in adult patients with glaucoma and is currently under investigational use in the US as part of an ongoing IDE study (FDA). The ExTra II (laser class 4) has the brand name ELIOS. The ExTra II is equivalent to ExTra and AIDA devices. 
Find out more about ELIOS : http://bit.ly/4lWBJZ1

Ver todos los episodios